Seven Peptides, One Regulatory Gray Zone: Inside the FDA's 503A Compounding Review

On April 22, 2026, the FDA quietly removed twelve peptides from its Category 2 list — the agency's designation for bulk drug substances that "may present significant safety risks" and are therefore prohibited from use in compounded drug products under Section 503A of the Federal Food, Drug, and Cosmetic Act. Among the twelve were seven substances that patients, clinicians, and compounding pharmacies have been using, debating, and litigating over for years: BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, and Epitalon.

The removal did not mean the FDA had approved these peptides, or concluded they were safe and effective, or reversed its earlier scientific assessments. It meant something more procedurally specific: the agency was clearing the regulatory deck ahead of a July 23–24, 2026 meeting of the Pharmacy Compounding Advisory Committee (PCAC), at which the committee will consider whether any of these substances should be affirmatively added to the 503A Bulks List — the positive list of substances that compounding pharmacies are permitted to use.

This is a meaningful distinction. The same PCAC, at its December 4, 2024 meeting, voted against recommending all seven of these peptides for inclusion on the 503A Bulks List. The July 2026 meeting is a re-review, not a first look. Understanding why the committee voted against inclusion in 2024 — and what, if anything, has changed since — requires understanding both the regulatory framework and the actual evidence base for each substance.

How the 503A Bulks List Works

Section 503A of the FD&C Act governs traditional compounding pharmacies — the pharmacies that prepare customized drug products for individual patients based on a valid prescription. Under 503A, a compounding pharmacy may use a bulk drug substance (a raw active pharmaceutical ingredient, rather than an FDA-approved finished drug) only if that substance appears on an FDA-approved list, or if it is a component of an FDA-approved drug, or if it appears on the United States Pharmacopeia (USP) or National Formulary.

The FDA maintains an interim framework for evaluating nominated bulk drug substances, organized into three categories. Category 1 substances are under active positive consideration for inclusion. Category 2 substances have been identified as presenting significant safety risks and are prohibited from compounding. Category 3 substances have insufficient data for a determination. The PCAC — an advisory committee of pharmacists, physicians, and scientists — reviews nominated substances and makes recommendations to the FDA, which retains final decision-making authority.

The interim policy governing this framework was published in the Federal Register on December 7, 2023 (88 FR 85308), with an updated version in January 2025. The April 2026 Category 2 removal was published at Federal Register Vol. 91, No. 73, Document 2026-07443, and the July 2026 PCAC meeting was announced in the same Federal Register issue (Document 2026-07361, Docket FDA-2025-N-6895).

The political context matters here. In March 2026, HHS Secretary Robert F. Kennedy Jr. publicly called for reversal of the peptide compounding restrictions, citing patient access and what he characterized as insufficient justification for the Category 2 designations. The April 2026 Category 2 removal followed. Whether the July 2026 PCAC will reach different conclusions than the December 2024 committee — given the same or similar evidence — is an open question.

What the December 2024 PCAC Found

The December 4, 2024 PCAC meeting (Docket FDA-2024-N-4777) reviewed all seven peptides and voted against recommending any of them for inclusion on the 503A Bulks List. The FDA's briefing documents for that meeting — available at regulations.gov under Docket FDA-2024-N-4777 — lay out the agency's concerns in detail. The pattern across all seven substances was consistent: animal data ranging from limited to extensive, human clinical trial data ranging from absent to limited, and no completed Phase II or Phase III trials meeting FDA standards for any of the seven.

The FDA's specific concerns included immunogenicity risk (the potential for synthetic peptides to trigger anti-drug antibody responses, which can range from reduced efficacy to serious hypersensitivity reactions), unknown pharmacokinetics in humans, purity and identity concerns for compounded preparations, and sterility risks associated with injectable formulations prepared outside pharmaceutical manufacturing standards. The agency's immunogenicity guidance for peptide therapeutics, published in 2023, outlines the assessment framework that none of these seven substances has been evaluated against in human studies.

The Seven Peptides: Evidence and Status

What follows is a summary of the evidence base and current regulatory status for each of the seven peptides under review. The evidence assessments reflect the published literature as of May 2026.

BPC-157

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide — fifteen amino acids — derived from a protein found in gastric juice. It is the most widely used of the seven in the compounding market, and it has the most extensive animal literature: over 500 published rodent studies examining wound healing, gastrointestinal protection, tendon repair, and anti-inflammatory effects. The nominated indication for the 503A Bulks List is ulcerative colitis.

The human clinical evidence is a different story. Croatian pharmaceutical company Pliva conducted early-phase trials under the names PL-10 and PL14736 for ulcerative colitis in the 1990s and early 2000s. A Phase II trial was initiated but the results were never fully published — referred to in the research community as "the ghost trial." As of early 2026, no completed, peer-reviewed Phase II or Phase III human clinical trial for BPC-157 has been published. STAT News, in a February 2026 investigation, described BPC-157 as a peptide with "big claims and scant evidence." BPC-157 is not approved in any major regulatory jurisdiction.

Additional safety concerns include pro-angiogenic properties that raise theoretical tumor-promotion questions, and the absence of any formal immunogenicity assessment in humans.

KPV

KPV is the C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (α-MSH) — specifically the last three amino acids, Lys-Pro-Val. It acts on melanocortin receptors (MC1R, MC3R) to suppress pro-inflammatory cytokines and inhibit NF-κB signaling. The nominated indications are wound healing and inflammatory conditions.

KPV's endogenous origin — it is a fragment of a naturally occurring human peptide hormone — is frequently cited as a favorable safety indicator. The preclinical evidence for anti-inflammatory effects in models of colitis, dermatitis, and systemic inflammation is reasonably consistent. The human clinical evidence is absent: no published human clinical trials for KPV have been identified in the peer-reviewed literature. The PCAC's December 2024 vote against inclusion reflected this gap.

TB-500

TB-500 is a synthetic peptide corresponding to amino acids 17–23 of the full 43-amino acid Thymosin Beta-4 (Tβ4) protein — specifically the actin-binding domain with the sequence LKKTETQ, believed to be responsible for most of Tβ4's tissue-repair activity. It is not the full Thymosin Beta-4 protein, and it is not Ac-SDKP, a separate four-amino acid N-terminal fragment of Tβ4 with distinct anti-fibrotic and hematopoietic properties. The nominated indication is wound healing.

The full Thymosin Beta-4 protein has been studied in Phase I and Phase II trials for cardiac repair by RegeneRx Biopharmaceuticals, but those trials evaluated the full protein, not the TB-500 fragment. No published human clinical trials for TB-500 specifically have been identified. The preclinical evidence for wound healing and anti-inflammatory effects is consistent with the broader Tβ4 literature. The FDA's concern about the distinction between the full protein and the synthetic fragment — and the absence of human pharmacokinetic data for the fragment — was reflected in the December 2024 PCAC vote.

MOTS-c

MOTS-c (Mitochondrial ORF of the Twelve S rRNA Type-C) is a 16-amino acid peptide encoded within the 12S rRNA region of mitochondrial DNA — one of a class of mitochondrial-derived peptides (MDPs) identified in the past decade. It was first characterized around 2015 and is proposed to regulate metabolic homeostasis via AMPK pathway activation. The nominated indications are obesity and osteoporosis.

MOTS-c is the most recently characterized of the seven peptides and has the thinnest clinical evidence base. Preclinical evidence for metabolic effects in rodent models is published (PMC4350682) and for bone effects in ovariectomized mice (PubMed PMID 27237975). One human clinical trial — NCT07505745, examining MOTS-c for insulin sensitivity in adults with prediabetes — was registered on ClinicalTrials.gov in 2026, indicating that early-stage human investigation is just beginning. No results have been published.

Emideltide (DSIP)

Emideltide is the INN (International Nonproprietary Name) for Delta Sleep-Inducing Peptide (DSIP), a nonapeptide originally isolated from rabbit cerebral venous blood in 1974 by Monnier and Hosli. CAS number 62568-57-4. The nominated indications are opioid withdrawal, chronic insomnia, and narcolepsy.

Emideltide has the oldest research history of the seven peptides, with small human studies from the 1980s and 1990s — primarily from European and Soviet literature — examining sleep induction and opioid withdrawal. These studies are generally small, methodologically limited by modern standards, and have not been replicated in contemporary controlled trials. No Phase II or Phase III trials meeting current FDA standards have been published. The mechanism of action remains incompletely characterized.

Semax

Semax is a synthetic heptapeptide analog of ACTH(4–10), developed in Russia at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is the most clinically developed of the seven peptides in terms of published human data. The nominated indications are cerebral ischemia and trigeminal neuralgia.

Semax is approved in Russia as a prescription drug for cerebral ischemia (acute and recovery phases), trigeminal neuralgia, cognitive and memory disorders, and optic nerve disease. Published clinical evidence includes a 2018 meta-analysis in the Bulletin of Rehabilitation Medicine on Semax effectiveness in acute stroke, a 2018 clinical study in the Journal of Neurology and Psychiatry on efficacy at different stages of ischemic stroke, and a 2001 clinical-electrophysiological study (PubMed PMID 11517472) in acute hemispheric ischemic stroke. A 2009 molecular study in Cellular and Molecular Neurobiology demonstrated that Semax activates BDNF and NGF transcription after cerebral ischemia in animal models.

The FDA does not recognize Russian drug approval as equivalent to FDA approval, and the Russian clinical literature has not been replicated in large-scale Western RCTs meeting FDA standards. No IND has been filed with the FDA for Semax. In Australia, Semax is not TGA-registered as an approved medicine but is available through the Special Access Scheme and compounding pathways. Semax's Russian approval history gives it a stronger evidentiary foundation than the other six peptides, but the evidence has not been evaluated through the FDA's standard review process.

Epitalon

Epitalon (also spelled Epithalon in Russian literature) is a synthetic tetrapeptide — Ala-Glu-Asp-Gly (AEDG) — derived from the pineal gland peptide Epithalamin. It was developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. The nominated indication is insomnia, based on the proposed mechanism of stimulating the pineal gland to produce melatonin.

The published clinical literature for Epitalon originates almost entirely from Khavinson's group and has not been independently replicated in Western controlled trials. A 2025 PMC review article provides a broad evidence overview (PMC11943447). A 2025 PubMed-indexed study examined Epitalon's effect on telomere length in human cell lines — a finding that has attracted attention in longevity circles but also raises theoretical oncological concerns that have not been formally evaluated. No Phase II or Phase III trials meeting FDA standards have been published. Epitalon is not approved as a pharmaceutical drug in any Western regulatory jurisdiction.

The Gray Zone: What Removal from Category 2 Actually Means

The April 2026 removal of these seven peptides from Category 2 created a regulatory situation without clear precedent. They are no longer explicitly prohibited from compounding under the Category 2 designation. They are not on the 503A Bulks List, which would affirmatively permit their use. They are not FDA-approved drugs. They exist in a gray zone in which their legal status for compounding is genuinely ambiguous pending the July 2026 PCAC determination.

For compounding pharmacies, this ambiguity is practically significant. The FDA's September 2025 coordinated enforcement wave — warning letters to Amazing Meds, Curex, Lovely Meds, SimpleRx, Healthy Male, All American Wellness, JulyMD, Fancy Meds, DirectMeds, and others — targeted compounded peptide products including BPC-157. Import Alert 66-80 continues to apply to bulk peptide APIs at the border. The removal from Category 2 does not retroactively resolve those enforcement actions or provide a clear safe harbor for pharmacies that resume compounding these substances before the July PCAC meeting.

The claim that the Category 2 designations were based on "lack of evidence rather than evidence of harm" is partially accurate but incomplete. The FDA's framework for 503A Bulks List inclusion requires affirmative evidence of safety and efficacy — the absence of harm reports is not sufficient for inclusion. The December 2024 PCAC's concerns were not primarily about documented adverse events in compounded peptide users; they were about the absence of the human pharmacokinetic, immunogenicity, and efficacy data that would be required to evaluate safety and efficacy systematically.

The distinction matters because "no reported harms" and "demonstrated safe" are not equivalent. Compounded peptide products are not subject to the adverse event reporting requirements that apply to approved drugs, which means the absence of a harm signal in the compounding market reflects, in part, the absence of systematic surveillance.

What the July 2026 PCAC Will Need to Evaluate

For the July 2026 PCAC to reach different conclusions than the December 2024 committee, the evidence base for these substances would need to have changed materially — or the committee's interpretation of the existing evidence would need to shift. The former is possible for MOTS-c, where a human clinical trial was registered in 2026, and for Semax, where the Russian clinical literature could be evaluated more favorably under a different interpretive framework. For BPC-157, KPV, TB-500, Emideltide, and Epitalon, the published human clinical evidence has not changed substantially since December 2024.

The public comment period for Docket FDA-2025-N-6895 closes July 9, 2026 — two weeks before the PCAC meeting. Comments from clinicians, patients, compounding pharmacies, and researchers will be part of the record the committee reviews. The PCAC's recommendations are advisory; the FDA retains final authority over the 503A Bulks List.